Jack A. Khattar - 14 Sep 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
14 Sep 2022
Transactions value $
-$46,575
Form type
4
Filing time
15 Sep 2022, 17:15:50 UTC
Previous filing
18 Aug 2022
Next filing
17 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +5,895 +0.76% $0 781,454 14 Sep 2022 Direct
transaction SUPN Common Stock Options Exercise -$46,575 -1,380 -0.18% $33.75 780,074 14 Sep 2022 Direct F1, F2
holding SUPN Common Stock 1,047,700 14 Sep 2022 By the KBT Trust
holding SUPN Common Stock 4,000 14 Sep 2022 By son F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Stock Appreciation Right Options Exercise $0 -5,895 -100% $0* 0 14 Sep 2022 Common Stock 5,895 $7.9 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.
F2 The price reported in Column 4 is the closing price of the common stock on August 29, 2022, the date of the SAR's exercise, as reported by NASDAQ Stock Market, LLC.
F3 The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose.
F4 The SAR vested in four equal annual installments beginning on February 5, 2014.